Ticker Details
MacroGenics, Inc. Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
IPO Date:	October 10, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$261.17M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.43%
Avg Daily Range (30 D):	$0.15 | 3.75%
Avg Daily Range (90 D):	$0.15 | 3.91%

Institutional Daily Volume
Avg Daily Volume:	.6M
Avg Daily Volume (30 D):	.6M
Avg Daily Volume (90 D):	.84M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	88
Avg Trade Size (Sh.) (90 D):	94

Institutional Trades
Total Institutional Trades:	2,303
Avg Institutional Trade:	$1.68M
Avg Institutional Trade (30 D):	$.68M
Avg Institutional Trade (90 D):	$2.37M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.74M
Avg Closing Trade (30 D):	$.73M
Avg Closing Trade (90 D):	$3.56M
Avg Closing Volume:	118.29K

News

Feb 26, 2026 @ 10:30 PM MacroGenics to Participate in Upcoming Investor Co... Source: Na

Feb 23, 2026 @ 11:14 PM MacroGenics Announces Pausing of Enrollment of New... Source: Macrogenics, Inc.

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 14, 2025 @ 8:21 PM MacroGenics Revenue Doubles in Q2 Source: Jesterai

Feb 6, 2025 @ 7:40 PM Investigation Alert: MacroGenics, Apellis Pharmace... Source: Johnson Fistel, Llp

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.22	$.31	$-.58
Diluted EPS	$-.22	$.31	$-.58
Revenue	$153.62M	$32.83M	$20.78M
Gross Profit
Net Income / Loss	$-14.59M	$19.52M	$-36.77M
Operating Income / Loss	$-45.28M	$-13.85M	$-33.44M
Cost of Revenue
Net Cash Flow	$-16.78M	$47.39M	$9.3M
PE Ratio